Purpose: The aim of this study was to investigate if common functional antioxidant polymorphisms are associated with epilepsy after neonatal hypoxic-ischemic encephalopathy (HIE). The antioxidant enzymes manganese superoxide dismutase (SOD2), glutathione peroxidase 1 (GPX1) and catalase (CAT) represent the primary defence mechanism against reactive oxygen species (ROS). Evidence suggests that genetic variants in antioxidant enzymes could influence susceptibility to epilepsy, but to date the relationship between them remains unclear. Methods: The study comprised 214 patients with epilepsy (64 with and 150 without neonatal HIE) as well as 95 healthy controls. Genomic DNA was isolated from buccal swabs or venous blood samples and genotyped for SOD2 rs4880, GPX1 rs1050450 and CAT rs1001179 using real-time PCR-based methods. Results: The investigated polymorphisms influenced neither the overall risk of epilepsy nor the risk of epilepsy after HIE in comparison with healthy controls. Furthermore, no significant difference in genotype distribution was observed between patients with drug-resistant epilepsy and patients in remission in either the group with epilepsy but without HIE or in the group with epilepsy and HIE, although the frequency of drug-resistant cases was higher in the latter group (p = 0.009, OR = 2.52; 95% CI = 1.22-4.15). Conclusion: According to this study, common GPX1, SOD2 and CAT polymorphisms do not influence the overall risk of epilepsy after HIE and its drug resistance.
Introduction
Hypoxic-ischemic encephalopathy (HIE) develops as a consequence of intrauterine or perinatal hypoxia associated with a variety of maternal, placental and/or foetal conditions [1] . Perinatal asphyxia-oxygen deficit at delivery [2] leads to a cascade of neurotoxic events involving energy failure and the accumulation of reactive oxygen species (ROS) [3, 4] . In the immature brain with its reduced capacity for defence against ROS, in particular due to lower glutathione peroxidase activity, the resultant tissue damage may lead either to 'minimal brain damage disorders' (attention deficits and hyperactivity) or to more severe neurological lifelong pathologies such as epilepsy and cerebral palsy (CP) or both [2, [5] [6] [7] .
Antioxidant enzymes represent an important defence mechanism against ROS. It has been suggested that generation of oxidative stress within the brain tissue might play an important role in epileptogenesis [8] , and several studies have investigated whether antioxidant enzyme activity influences either susceptibility to epilepsy or its characteristics such as drug resistance [9, 10] .
Antioxidant enzymes such as manganese superoxide dismutase (SOD2), glutathione peroxidase (GPX1) and catalase (CAT) detoxify superoxide anion and hydrogen peroxide and constitute the primary defence against ROS. The activity of these antioxidant enzymes protects cells from ROS and is influenced by functional genetic polymorphisms. GPX1 rs1050450 polymorphism leads to p. Pro198Leu substitution with the Leu variant being less active than its Pro counterpart [11] . SOD2 rs4880 polymorphism alters the amino acid in the mitochondrial leading sequence (p.Ala16Val) resulting in lower MnSOD activity [12] . The CAT rs1001179 (c.-262 C > T) polymorphism alters the transcription factor binding site in the promoter region [13] , with the polymorphic T allele leading to enhanced gene transcription, but its association with enzyme activity is more complex [14, 15] . The aim of this study was to investigate if functional polymorphisms in antioxidant genes contribute to susceptibility to epilepsy after neonatal HIE and/or its drug-resistance.
Methods

Participants
Two hundred and fourteen patients-children and adolescents of Slovenian Central European Caucasian origin with epilepsy were consecutively recruited during their regular outpatient follow-up visits in our hospital during the period January 2011-December 2014. The medical data of all patients were collected retrospectively from electronic and/or paper records. In particular, data from the neonatal period regarding the level of consciousness, activity, neuromuscular control, complex/primitive reflexes, autonomic functions in a newborn and the presence of seizures were reviewed. The patients were divided into two groups according to the aetiology of their epilepsy. The inclusion criterion for the first group was documented neonatal hypoxic-ischemic encephalopathy (HIE) grades II-III, according to the Sarnat and Sarnat classification [16] . This group has been a part of our previous research [17] . The Sarnat and Sarnat Grading Scale was used, as it represents a valid tool for clinical assessment of HIE for both clinical and research purposes in the neonatal period [16, 18] . Only neonates, that were expected to be healthy newborns, but suffered an episode of acute perinatal hypoxia with Apgar score <5 at 5 min, foetal umbilical artery pH <7.0 were included in the first study group. Perinatal, neonatal risk factors and cranial US scans, which were a part of routine clinical care, were reviewed, while neonatal MRI brain scans (adjusted for age in preterms) were not performed as a routine clinical work in one third of patients. The exclusion criteria for the first group were HIE grade I and the presence of any other concurrent medical condition that may itself lead to the development of epilepsy (intrauterine growth retardation, neonatal sepsis, congenital heart disease, brain malformation, genetic, metabolic or any other disorders that may be associated with neonatal encephalopathy). Patients with insufficient data regarding perinatal history were also excluded.
The inclusion criterion for the second group was a diagnosis of epilepsy regardless of the cause, but with no perinatal HIE (i.e. documented normal pregnancy and perinatal data). Collected clinical data for all patients consisted of gender, date of birth, gestational age, aetiology of epilepsy and the responsiveness of seizures to drug treatment. The latter was classified as epilepsy in remission if no seizures occurred in the last year, or as drugresistant epilepsy if at least one seizure occurred in the last year of the follow up.
The control group consisted of 95 healthy Slovenian blood donors younger than 30 years of age at the time of blood sampling. The study was approved by the Republic of Slovenia National Medical Ethics Committee and written informed consent was obtained from all the participants and/or their parents or legal guardians prior to inclusion in the study.
DNA isolation and genotyping
Venous blood samples or buccal swabs were obtained for DNA extraction. Samples of 3 ml blood were collected from 150 participants during their regular outpatient visits. DNA was isolated using the FlexiGene DNA Kit (Qiagen, Hilden, Germany). Buccal swabs were obtained from 64 patients who did not need regular blood control. The DNA Mini Kit (QIAGEN) was used for DNA extraction from buccal swabs according to the recommended protocol. DNA from healthy controls was also isolated from venous blood using the FlexiGene DNA Kit (Qiagen). For GPX1 rs1050450 and SOD2 rs4880, genotyping was performed using TaqMan genotyping assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions as previously described [19] . Genotypes of CAT rs1001179 were determined using KASPar assay (KBiosciences, Herts, UK) according to the recommended protocol [20] .
The frequencies, median and the interquartile range were used to describe the distribution of categorical and continuous variables, respectively. To assess deviation from Hardy-Weinberg equilibrium (HWE), a standard chi-square test was used. A dominant model was used in all analyses. To assess the effect of polymorphisms on susceptibility to epilepsy and drug resistance, we calculated odds ratios (ORs) and 95% confidence intervals (95% CI) using logistic regression analysis. Statistical analysis was performed using IBM SPSS Statistics, version 19.0 (IBM Corporation, Armonk, NY, USA). A p < 0.05 or less was considered statistically significant.
To determine the effect size that we could detect based on the minor allele frequency of investigated polymorphisms, we used the Power and Sample Size Calculation programme version 3.0.43 [21] . In the case-control analysis, we were able to detect with 80% power ORs above 2.13 for GPX1, above 2.01 for SOD2 and above 2.07 for CAT.
Results
The overall study population included 214 patients with epilepsy, 64 (29.9%) with HIE and 150 (70.1%) with other causes of epilepsy and no HIE. Baseline characteristics of all patients are presented in Table 1 . Of the 95 healthy controls, 46 (48.9%) were male and the median age was 21 (20-23) years. Genotype frequencies for SOD2 rs4880, GPX1 rs1050450 and CAT rs1001179 are shown in Table 2 . The genotype distributions of the studied polymorphisms were in Hardy-Weinberg equilibrium (HWE) among the controls. The frequency distribution of GPX1 rs1050450, SOD2 rs4880 and CAT rs1001179 among patients with epilepsy did not differ significantly from healthy controls (p = 0.261, p = 0.649, p = 0.534) ( Table 2 ). Although there were more patients with at least one polymorphic GPX1 rs1050450 T allele in the group of patients with epilepsy after HIE (N = 64) compared to healthy controls (57% versus 45%), the difference was not statistically significant (p = 0.127). The distribution of CAT rs1001179 and SOD2 rs4880 among patients with epilepsy after HIE was similar to controls (p = 0.337 and p = 0.701, respectively).
There were also no significant differences in genotype distributions between patients with epilepsy after HIE and patients with epilepsy without HIE (all p values >0.05, Table 3 ).
Drug-resistant epilepsy and antioxidant gene polymorphisms
Among all 214 patients with epilepsy, 105 (49.50%) achieved remission and 107 (50.50%) had drug-resistant epilepsy, while data regarding seizures were inconclusive for two patients. Several clinical characteristics were associated with drug resistance: patients with epilepsy and HIE were more likely to be drugresistant than patients with epilepsy without HIE (p = 0.009, OR = 2.25; 95% CI = 1.22-4.15). Patients with epilepsy who also had CP developed drug-resistant epilepsy more frequently (p = 0.006, OR = 2.60; 95% CI = 1.31-5.15). Gender was not associated with drug resistance (p = 0.498), but age was, with older patients being more often in remission (p = 0.039, OR = 0.96; 95% CI = 0.92-1.00). Due to correlations between variables, we included age and the presence of CP in the multivariable model. The distribution of GPX1 rs1050450, SOD2 rs4880 or CAT rs1001179 did not differ between patients in remission and patients with drug resistance in univariable analysis (p = 0.450, p = 0.401 and p = 0.745, respectively). Multivariable analysis also showed that there were no significant associations between polymorphisms and drug resistance (Table 4 ).
In the group of 64 patients with epilepsy and HIE, only 22 (35.50%) patients achieved remission. None of the clinical variables was associated with drug resistance in this group. The distribution of the polymorphic genotypes among HIE patients in remission and HIE patients with drug resistance differed only for GPX1 rs1050450, but this was not statistically significant (p = 0.227). No differences were observed regarding the distribution of SOD2 rs4880 and CAT rs1001179 among these two subgroups (p = 0.470 and p = 0.568, respectively) ( Table 4 ).
Discussion
To the best of our knowledge, this study is the first report on the role of antioxidant enzyme polymorphisms in epilepsy after HIE and its drug resistance, taking into consideration the common genetic variants of the key enzymatic ROS scavengers. Although we expected that a difference would be found in the distribution of antioxidant enzyme polymorphisms in the HIE group in comparison to non HIE group, we demonstrated that GPX1 rs1050450, SOD2 rs4480 and CAT rs1001179 are neither associated with the development of epilepsy after HIE nor with its drug resistance.
The overall number of epilepsy patients in remission was comparable to those with no remission (105 and 107, respectively) and the groups did not differ in the distribution of antioxidant enzyme polymorphisms. However, the distribution of the polymorphic genotypes among HIE patients in remission and HIE patients with drug resistant epilepsy tended to be different for GPX1 rs1050450 only, but this was not statistically significant (p = 0.227).
The brain is an organ that consumes the highest amount of oxygen in the human body. The lack of antioxidant enzyme production and the rapidly developing brain tissue, which is thus overloaded with aerobic metabolism, renders newborns highly susceptible to oxidative damage. [22] . The increased level of ROS during acute hypoxic-ischemic events may lead to tissue damage with neurological deficits. The same mechanisms might be involved in epileptogenesis after HIE, together with the inflammatory cascade, which simultaneously occurs during acute brain hypoxemia, and the ongoing structural changes in the neuronal network [3] . The inflammation is also closely involved in the production of ROS and may aggravate the burden of oxidative stress. To understand these mechanisms better, a prospective study using an early MRI in addition to the clinical and laboratory criteria of acute brain hypoxia would be the most suitable approach.
As it has been widely reported that alterations in the antioxidant system and increases in oxidants are associated with epilepsy, we hypothesised that the reduced capacity for defence against ROS may itself be responsible for epileptogenesis in the damaged brain tissue. To date, some studies have already suggested the possibility of the implication of antioxidant enzymes in the generation of epilepsy. Rumia et al. analysed antioxidant enzyme levels in surgical brain specimens of patients with epilepsy and demonstrated an increase in catalase CAT and a decrease in GPX levels, together with no change in SOD levels. Their results thus suggest that CAT is the main enzymatic antioxidant in the human epileptic neocortex, while GPX and SOD did not appear to be major free radical scavenger systems in epilepsy [23] . In addition, our previous study showed that CAT rs1001179 polymorphism has been statistically significantly associated with cerebral palsy in patients after HIE, even after taking prematurity into consideration in the multivariable analysis [17] .
It has been proposed that reduced GPX1 activity or its polymorphisms might serve as an early biomarker of later neurological sequelae [5] [6] [7] , but we found no such association regarding the development of epilepsy. One study concluded that Table 2 Comparison of genotype distributions of the studied polymorphisms between healthy controls and all patients with epilepsy (N = 214) or patients with epilepsy after HIE (N = 64), respectively. progressive myoclonic epilepsy is not associated with plasma and erythrocyte GPX and CAT activity. Yet another study in patients with epilepsy found GPX activity was significantly higher in the hippocampus of patients after a ketogenic diet, which implies that higher GPX activity might be one of the mechanisms by which this diet exerts its anti-seizure effects [9, 10] . It could be speculated that the ketogenic diet itself enhances this enzyme activity. However, although rare, the above-mentioned studies point out the possible role of the enzyme level or activity in relation to the drug-resistant form of epilepsy, although they mostly measured enzyme activities or enzyme levels and not the association with genetic polymorphisms. Consequently, our study is only comparable to previous studies to a limited extent, since it is still not clearly understood how the investigated polymorphisms affect enzyme activities or their levels. A recent study suggested that the genetic polymorphisms of glutathione transferases (GSTs) might be associated with the enhanced susceptibility to oxidative stress in patients with progressive myoclonous epilepsy [24] . Since these genetic polymorphisms were not investigated in our study, this indication certainly advocated additional research regarding the association of GST polymorphisms with epilepsy after HIE.
Our study had several limitations: the number of patients in the study group with HIE was rather small and heterogeneous since some premature patients had HIE combined with subependimal and intraventricular haemorrhage. The number of patients with haemorrhage was small, so it was not possible to study them separately. It is well known that many intrinsic pathophysiological mechanisms are involved during hypoxic-ischemic events leading to hypoxic-ischemic neonatal brain injury and its sequelae. As it would be impossible to retrospectively evaluate each of them, we decided to use the Sarnat and Sarnat classification as a wellrecognised tool for the clinical assessment of HIE. Another limitation of this study relates to the involvement of neonates with gestational ages ranging from premature to mature. Different results might have been obtained for the groups stratified for gestational age, but the number of patients was insufficient for statistical analysis to be performed separately for the two gestational groups. Furthermore, to understand the impact of genetic polymorphisms more precisely, the next step in the research would be a prospective study of a cohort of neonates with HIE but not developing epilepsy in comparison to those developing epilepsy.
Nevertheless, the novelty of our study is that it is one of the first studies to investigate the associations of antioxidant polymorphisms with epilepsy as there are very limited data on antioxidant enzyme polymorphism in relation to the risk of epilepsy.
Conclusions
Our study demonstrates that SOD2 rs4880, GPX1 rs1050450 and CAT rs1001179 are not associated with an increased susceptibility to epilepsy after HIE or its drug resistance. These results notably contribute to the knowledge of the pathophysiology of epilepsy. According to the evidence of the implication of oxidative stress in the pathogenesis of epilepsy described in several previous studies, further insight into genetic variants of antioxidant enzymes is needed. 
